Cargando…
Dexamethasone Therapy of Congenital Adrenal Hyperplasia and the Myth of the “Growth Toxic” Glucocorticoid
The use of long-acting glucocorticoids in the treatment of individuals with Congenital Adrenal Hyperplasia (CAH) has been greeted with controversy. Avoidance of dexamethasone therapy is in part due to the mistaken assumptions that dexamethasone is 30-fold more potent than hydrocortisone in suppressi...
Autor principal: | Rivkees, Scott A. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2855951/ https://www.ncbi.nlm.nih.gov/pubmed/20414340 http://dx.doi.org/10.1155/2010/569680 |
Ejemplares similares
-
Low-Dose Dexamethasone Therapy from Infancy of Virilizing Congenital Adrenal Hyperplasia
por: Rivkees, Scott A., et al.
Publicado: (2009) -
Pharmacogenomic markers of glucocorticoid response in congenital adrenal hyperplasia
por: Botelho Barra, Cristina, et al.
Publicado: (2022) -
An update on the long-term outcomes of prenatal dexamethasone treatment in congenital adrenal hyperplasia
por: van’t Westeinde, Annelies, et al.
Publicado: (2023) -
Growth and Reproductive Outcomes in Congenital Adrenal Hyperplasia
por: Nebesio, Todd D., et al.
Publicado: (2010) -
Congenital adrenal hyperplasia
por: Dessinioti, Cleo, et al.
Publicado: (2009)